Summary This case study reviews a recent capacity expansion project led by a top European biopharmaceutical manufacturer and executed in partnership with LYOMAC TECHNOLOGY LTD. The engagement covered supply of multiple Lyopro vial freeze dryer lines, ALUS integration, FAT/SAT, and full validation support. The result: on-time commissioning, validated performance, and accelerated commercial supply.
Project background A leading European biologics company planned to expand commercial lyophilized product capacity to meet rising demand for complex sterile injectables and diagnostic reagents. Key requirements included scalable production (vial freeze dryer capacity ranging from pilot to commercial Lyopro-500 and Lyopro-1000 units), CIP/SIP compliance, Part 11-capable automation, and minimized installation risk to meet a tight regulatory timeline.
LYOMAC solution and scope LYOMAC TECHNOLOGY LTD supplied a turnkey solution:
· Two Lyopro-1000 vial freeze dryer lines configured for aseptic integration and CIP/SIP coverage.
· Lyopro-ALUS automated loading/unloading systems synchronized with the client’s filling line and isolator interface.
· GAMP 5-aligned SCADA with Part 11 features and historian for electronic batch records.
· Comprehensive FAT at LYOMAC facilities, followed by SAT, IQ/OQ support, and PQ assistance on site.
· Validation documentation templates, operator training, and lifecycle service agreements.
· Customized condenser sizing to handle peak vapor loads for high-fill vials.
· Precision stoppering integration and in-chamber stoppering sequences to preserve sterility.
· Advanced vacuum control with cascade loops to maintain stable sublimation during heavy loads.
· CIP spray coverage mapping and validated SIP cycles with thermocouple verification and biological indicator guidance.
· Successful FAT sign-off and on-site SAT completed within scheduled windows.
· First commercial batches met residual moisture and reconstitution specifications on first release.
· Regulatory submission supported by LYOMAC’s validation packages; audit responses facilitated by LYOMAC documentation.
· Reduced ramp-up time due to hands-on training and on-site process development assistance.
Lessons and broader implications This project exemplifies how integrated supplier capabilities—engineering, automation, validation, and global service—reduce implementation risk for major expansion projects. LYOMAC’s end-to-end offering enabled the client to focus on product supply while outsourcing complex equipment integration and qualification.
Contact LYOMAC TECHNOLOGY LTD — sales@lyomac.comSelected references1. EMA (2022). EU GMP Annex
1: Manufacture of Sterile Medicinal Products.
2. ISPE (2018). Baseline Guide: Sterile Product Manufacturing Facilities.
3. PDA (2013). Technical Report: Process Simulation Testing for Aseptically Filled Products.
